Gait, Balance and Functional Assessments for DCT and Hybrid Trials

BioSensics is excited to announce that its LEGSys and BalanSens now support both fully-remote and remotely-supervised assessments of gait and balance via their integration into BioDigit Home. 

LEGSys and BalanSens are the first FDA-listed wearable devices for clinical gait and balance assessments. They have been used in 200+ clinical studies and trials. In 15+ clinical trials, the devices are used to capture the primary endpoints of trials.

This integration enables inclusion of gait, balance and functional assessments in decentralized and hybrid clinical trials. This new platform is empowering a fully remote observational study in Progressive Supranuclear Palsy and Parkinson's Disease at Mass General Hospital and Johns Hopkins. 

BioDigit Home is the most comprehensive solution for the measurement of digital biomarkers in CNS diseases. BioDigit Home includes more than 100 digital assessments for the measurement and monitoring of motor, cognition, and speech functions, as well as mental health. 

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that develops and provides end-to-end solutions and services for the collection of digital measures and biomarkers in clinical trials and research. All components of BioSensics solutions, including the wearable sensors, software, and algorithms are developed and validated by BioSensics. Our experienced research team provides comprehensive technical and scientific consulting, including study design and protocol development support, as well as statistical analysis. In addition, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

The U.S. National Institute of Health (NIH) has awarded BioSensics over $50M to support its research and development programs. In 2022, NIH selected BioSensics to develop remote measurement technologies for use in clinical trials in individuals with rare diseases.